Skip to content

Experimental study of Shengpu Huang Decoction in treating cerebral microhemorrhage complicated with cognitive dysfuction

Experimental study of Shengpu Huang Decoction in treating cerebral microhemorrhage complicated with cognitive dysfuction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001741
Enrollment
Unknown
Registered
2025-09-15
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral microhemorrhage

Interventions

experimental goup:Shengpu Huang

Sponsors

Wujin Hospital of Traditinonal Chinese Medicine Changzhou City Jiangsu Prvince
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: A total of 40 patients with cerebral microbleeds met the following criteria. The enrolled patients met the following conditions: 1. Age ranging from 50 to 85 years old; 2. Detected cerebral microbleeds = 5 by susceptibility-weighted magnetic resonance imaging; 3. Modified Mini-Mental State Examination (MMSE) score: illiterates = 17 points, primary school students = 20 points, junior high school students = 23 points, and college graduates = 26 points; 4. Signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Presence of consciousness disorders, severe language, comprehension or cognitive functional impairments, and inability to complete intelligence scale examinations; 2. Concurrently suffering from other neurological-related diseases outside of stroke, such as brain trauma, cerebral vascular malformations, brain tumors or brain edema, etc.; 3. Suffering from chronic somatic diseases and undergoing treatment, such as cancer, chronic heart disease, chronic renal failure, severe chronic blood system diseases, etc.; 4. Suffering from mental system-related diseases or having a history of hereditary mental disorders, including schizophrenia, bipolar disorder; 5. Patients with severe liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
magnetic resonance;

Secondary

MeasureTime frame
Blood Aß;Blood Phosphoric Tau;Improved MISS Scale Score;

Countries

China

Contacts

Public ContactHuafeng Jin

Wujin Hospital of Traditinonal Chinese Medicine Changzhou City Jiangsu Prvince

jhf58@hotmal.cm13701498182

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026